Table 3:
Treatment a
| Treatment | White (n = 628) | Black (n = 164) | Hispanic (n = 660) | Asian (n = 255) |
p value |
|---|---|---|---|---|---|
| Revascularization | |||||
| PCI | 490 (78.0) | 116 (70.7) | 466 (70.6) | 186 (72.9) | 0.02 |
| CABG | 59 (9.4) | 19 (11.6) | 80 (12.1) | 39 (15.3) | 0.09 |
| PCI/CABG | 524 (83.4) | 130 (79.3) | 524 (79.4) | 216 (84.7) | 0.12 |
| Medications (filled at least 1 prescription postdischarge) |
|||||
| Statin | 594 (94.6) | 148 (90.2) | 618 (93.6) | 240 (94.1) | 0.24 |
| Beta-blockers | 591 (94.1) | 153 (93.3) | 620 (93.9) | 246 (93.9) | 0.43 |
| ACEI/ARB | 536 (85.4) | 135 (82.3) | 559 (84.7) | 219 (85.9) | 0.76 |
| P2Y12 inhibitors | 575 (91.6) | 144 (87.8) | 578 (87.6) | 229 (89.8) | 0.12 |
| Medication adherence (among patients with a last 1 year of follow-up) |
(n = 622) | (n = 159) | (n = 654) | (n = 249) | |
| Statin PDC ≥ 80% | 419 (67.4) | 80 (50.3) | 383 (58.6) | 180 (72.3) | < 0.001 |
| Beta-blockers PDC ≥ 80% | 417 (67.0) | 99 (62.3) | 394 (60.2) | 189 (75.9) | < 0.001 |
| ACEI/ARB PDC ≥ 80% | 367 (59.0) | 90 (56.6) | 382 (58.4) | 154 (61.9) | 0.73 |
| P2Y12 inhibitors PDC ≥ 80% | 429 (69.0) | 93 (58.5) | 412 (63.0) | 187 (75.1) | < 0.001 |
a
The measurement period used in this study was the first year after discharge from hospitalization for myocardial infarction.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PDC, proportion of days covered, with PDC ≥ 80% indicating good adherence to medication during the measurement period; P2Y12, P2Y12 receptor.